We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Valeant (VRX) Stock Slides 4% on Debt Restructuring Announcement
Read MoreHide Full Article
Pharmaceutical and biotech company Valeant Pharma slipped down 4.33% to $12.50 intraday Monday due to an announcement of debt restructuring. Negatively impacting EPS, the company announced it paid $1.1 billion in loans after selling their skincare assets to L’Oreal (LRLCY - Free Report) .
Valeant is being suffocated under $31 billion of debt and now the company is managing the task of efficiently and effectively maintaining steady cash flow streams in order to pay down the debt.
In the past year, Valeant has been scrutinized for accounting fraud. Pointing fingers at former CFO Howard Schiller, the company’s stock has fallen 80% since March of 2016. The previous accounting scandal and current debt levels are the biggest factors in their struggling stock price. If Valeant can properly manage their debt amounts, the company’s stock, which was once trading at $257 per share, is expected to reasonably recover from its current trading level.
On Monday, Valeant announced they will be refinancing and amending their current credit agreement. With that, the company looks to borrow new Term B loans and issue new debt securities in order to extend any maturity dates before 2022. Additionally, Valeant looks to pay off all Term A loans.
There are positives and negatives to these moves: positively, a small portion of their debt is paid off. Negatively, in a hawkish interest rate environment, pushing off paying billions of dollars in debt may not be what Valeant exactly needs under their debt stress.
The refinancing is expected to close in the first quarter of 2017, if completed.
The market is reacting negatively Monday due to the hit Valeant’s EPS will take from their debt restructuring. David Marris, a pharmaceutical analyst from Well Fargo (WFC - Free Report) , stated that Wells Fargo is “still working through how much this will negatively impact consensus EPS, but we believe that it will lower consensus EPS”.
8 Stocks with Huge Profit Potential
Just released: Driverless Cars: Your Roadmap to Mega-Profits Today. In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Valeant (VRX) Stock Slides 4% on Debt Restructuring Announcement
Pharmaceutical and biotech company Valeant Pharma slipped down 4.33% to $12.50 intraday Monday due to an announcement of debt restructuring. Negatively impacting EPS, the company announced it paid $1.1 billion in loans after selling their skincare assets to L’Oreal (LRLCY - Free Report) .
Valeant is being suffocated under $31 billion of debt and now the company is managing the task of efficiently and effectively maintaining steady cash flow streams in order to pay down the debt.
In the past year, Valeant has been scrutinized for accounting fraud. Pointing fingers at former CFO Howard Schiller, the company’s stock has fallen 80% since March of 2016. The previous accounting scandal and current debt levels are the biggest factors in their struggling stock price. If Valeant can properly manage their debt amounts, the company’s stock, which was once trading at $257 per share, is expected to reasonably recover from its current trading level.
On Monday, Valeant announced they will be refinancing and amending their current credit agreement. With that, the company looks to borrow new Term B loans and issue new debt securities in order to extend any maturity dates before 2022. Additionally, Valeant looks to pay off all Term A loans.
There are positives and negatives to these moves: positively, a small portion of their debt is paid off. Negatively, in a hawkish interest rate environment, pushing off paying billions of dollars in debt may not be what Valeant exactly needs under their debt stress.
The refinancing is expected to close in the first quarter of 2017, if completed.
The market is reacting negatively Monday due to the hit Valeant’s EPS will take from their debt restructuring. David Marris, a pharmaceutical analyst from Well Fargo (WFC - Free Report) , stated that Wells Fargo is “still working through how much this will negatively impact consensus EPS, but we believe that it will lower consensus EPS”.
8 Stocks with Huge Profit Potential
Just released: Driverless Cars: Your Roadmap to Mega-Profits Today. In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>